▲ +10.58% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $186.78, with a high forecast of $233.00 and a low forecast of $128.00. The average price target represents a 10.58% upside from the last price of $168.90.
The current consensus among 18 investment analysts is to buy stock in Jazz Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.